

Individuals using assistive technology may not be able to fully access the information contained in this file. For assistance, please call 800-835-4709 or 240-402-8010, extension 1. CBER Consumer Affairs Branch or send an e-mail to: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov) and include 508 Accommodation and the title of the document in the subject line of your e-mail.

## HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use M-M-R II safely and effectively. See full prescribing information for M-M-R II.

**M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live)  
Suspension for intramuscular or subcutaneous injection  
Initial U.S. Approval: 1978**

### RECENT MAJOR CHANGES

Dosage and Administration  
Dose and Schedule (2.1)-----03/2023  
Administration (2.2)-----03/2023

### INDICATIONS AND USAGE

M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older. (1)

### DOSAGE AND ADMINISTRATION

For intramuscular or subcutaneous injection only. (2.1, 2.2).

A single dose is approximately 0.5 mL.

- The first dose is administered at 12 to 15 months of age. (2.1)
- The second dose is administered at 4 to 6 years of age. (2.1)

### DOSAGE FORMS AND STRENGTHS

Suspension for injection (approximately 0.5-mL dose) supplied as a lyophilized vaccine to be reconstituted using accompanying sterile diluent. (3)

### CONTRAINDICATIONS

- Hypersensitivity to any component of the vaccine. (4.1)
- Immunosuppression. (4.2)
- Moderate or severe febrile illness. (4.3)
- Active untreated tuberculosis. (4.4)
- Pregnancy. (4.5, 8.1)

### WARNINGS AND PRECAUTIONS

- Use caution when administering M-M-R II to individuals with a history of febrile seizures. (5.1)
- Use caution when administering M-M-R II to individuals with anaphylaxis or immediate hypersensitivity following egg ingestion. (5.2)
- Use caution when administering M-M-R II to individuals with a history of thrombocytopenia. (5.3)
- Evaluate individuals for immune competence prior to administration of M-M-R II if there is a family history of congenital or hereditary immunodeficiency. (5.4)
- Immune Globulins (IG) and other blood products should not be given concurrently with M-M-R II. (5.5, 7.2)

### ADVERSE REACTIONS

See full prescribing information for adverse reactions occurring during clinical trials or the post-marketing period. (6)

**To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., at 1-877-888-4231 or VAERS at 1-800-822-7967 or [www.vaers.hhs.gov](http://www.vaers.hhs.gov).**

### DRUG INTERACTIONS

- Administration of immune globulins and other blood products concurrently with M-M-R II vaccine may interfere with the expected immune response. (7.2)
- M-M-R II vaccination may result in a temporary depression of purified protein derivative (PPD) tuberculin skin sensitivity. (7.3)

### USE IN SPECIFIC POPULATIONS

- Pregnancy: Do not administer M-M-R II to females who are pregnant. Pregnancy should be avoided for 1 month following vaccination with M-M-R II. (4.5, 8.1, 17)

**See 17 for PATIENT COUNSELING INFORMATION and FDA-approved patient labeling.**

Revised: 03/2023

## FULL PRESCRIBING INFORMATION: CONTENTS\*

<b>1</b>	<b>INDICATIONS AND USAGE</b>
<b>2</b>	<b>DOSAGE AND ADMINISTRATION</b>
2.1	Dose and Schedule
2.2	Administration
<b>3</b>	<b>DOSAGE FORMS AND STRENGTHS</b>
<b>4</b>	<b>CONTRAINDICATIONS</b>
4.1	Hypersensitivity
4.2	Immunosuppression
4.3	Moderate or Severe Febrile Illness
4.4	Active Untreated Tuberculosis
4.5	Pregnancy
<b>5</b>	<b>WARNINGS AND PRECAUTIONS</b>
5.1	Febrile Seizure
5.2	Hypersensitivity to Eggs
5.3	Thrombocytopenia
5.4	Family History of Immunodeficiency
5.5	Immune Globulins and Transfusions
<b>6</b>	<b>ADVERSE REACTIONS</b>
<b>7</b>	<b>DRUG INTERACTIONS</b>
7.1	Corticosteroids and Immunosuppressive Drugs
7.2	Immune Globulins and Transfusions

7.3	Tuberculin Skin Testing
7.4	Use with Other Live Viral Vaccines
<b>8</b>	<b>USE IN SPECIFIC POPULATIONS</b>
8.1	Pregnancy
8.2	Lactation
8.4	Pediatric Use
8.5	Geriatric Use
<b>11</b>	<b>DESCRIPTION</b>
<b>12</b>	<b>CLINICAL PHARMACOLOGY</b>
12.1	Mechanism of Action
12.4	Persistence of Antibody Responses After Vaccination
<b>13</b>	<b>NONCLINICAL TOXICOLOGY</b>
13.1	Carcinogenesis, Mutagenesis, Impairment of Fertility
<b>14</b>	<b>CLINICAL STUDIES</b>
14.1	Clinical Efficacy
14.2	Immunogenicity
<b>15</b>	<b>REFERENCES</b>
<b>16</b>	<b>HOW SUPPLIED/STORAGE AND HANDLING</b>
<b>17</b>	<b>PATIENT COUNSELING INFORMATION</b>

\*Sections or subsections omitted from the full prescribing information are not listed.

---

## FULL PRESCRIBING INFORMATION

### 1 INDICATIONS AND USAGE

M-M-R II is a vaccine indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

### 2 DOSAGE AND ADMINISTRATION

**Intramuscular or Subcutaneous administration only.**

#### 2.1 Dose and Schedule

A single dose of M-M-R II is approximately 0.5 mL.

The first dose is administered at 12 to 15 months of age. A second dose is administered at 4 to 6 years of age.

The second dose may be administered prior to 4 years of age, provided that there is a minimum interval of one month between the doses of measles, mumps and rubella virus vaccine, live {1-2}.

Children who received an initial dose of measles, mumps and rubella vaccine prior to their first birthday should receive additional doses of vaccine at 12-15 months of age and at 4-6 years of age to complete the vaccination series [see *Clinical Studies (14.2)*].

For post-exposure prophylaxis for measles, administer a dose of M-M-R II vaccine within 72 hours after exposure.

#### 2.2 Administration

Use a sterile syringe free of preservatives, antiseptics, and detergents for each injection and/or reconstitution of the vaccine because these substances may inactivate the live virus vaccine. To reconstitute, use only the diluent supplied with the vaccine since it is free of preservatives or other antiviral substances which might inactivate the vaccine.

Withdraw the entire volume of the supplied diluent from its vial and inject into lyophilized vaccine vial. Agitate to dissolve completely. Discard if the lyophilized vaccine cannot be dissolved.

Withdraw the entire volume of the reconstituted vaccine and inject the vaccine intramuscularly or subcutaneously.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Visually inspect the vaccine before and after reconstitution prior to administration. Before reconstitution, the lyophilized vaccine is a light yellow compact crystalline plug, when reconstituted, is a clear yellow liquid. Discard if particulate matter or discoloration are observed in the reconstituted vaccine.

To minimize loss of potency, administer M-M-R II as soon as possible after reconstitution. If not used immediately, the reconstituted vaccine may be stored between 36°F to 46°F (2°C to 8°C), protected from light, for up to 8 hours. Discard reconstituted vaccine if it is not used within 8 hours.

### 3 DOSAGE FORMS AND STRENGTHS

M-M-R II vaccine is a suspension for injection supplied as a single dose vial of lyophilized vaccine to be reconstituted using the accompanying sterile diluent [see *Dosage and Administration (2.2)* and *How Supplied/Storage and Handling (16)*]. A single dose after reconstitution is approximately 0.5 mL.

### 4 CONTRAINDICATIONS

#### 4.1 Hypersensitivity

Do not administer M-M-R II vaccine to individuals with a history of hypersensitivity to any component of the vaccine (including gelatin) {3} or who have experienced a hypersensitivity reaction following administration of a previous dose of M-M-R II vaccine or any other measles, mumps and rubella-containing vaccine. Do not administer M-M-R II vaccine to individuals with a history of anaphylaxis to neomycin [see *Description (11)*].

#### 4.2 Immunosuppression

Do not administer M-M-R II vaccine to individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. Measles inclusion body encephalitis {4} (MIBE), pneumonitis {5} and death as a direct consequence of disseminated measles vaccine virus infection have been reported in

immunocompromised individuals inadvertently vaccinated with measles-containing vaccine. In this population, disseminated mumps and rubella vaccine virus infection have also been reported.

#### **4.3 Moderate or Severe Febrile Illness**

Do not administer M-M-R II vaccine to individuals with an active febrile illness with fever >101.3°F (>38.5°C).

#### **4.4 Active Untreated Tuberculosis**

Do not administer M-M-R II vaccine to individuals with active untreated tuberculosis (TB).

#### **4.5 Pregnancy**

Do not administer M-M-R II to individuals who are pregnant or who are planning on becoming pregnant within the next month [see *Use in Specific Populations (8.1) and Patient Counseling Information (17)*].

### **5 WARNINGS AND PRECAUTIONS**

#### **5.1 Febrile Seizure**

There is a risk of fever and associated febrile seizure in the first 2 weeks following immunization with M-M-R II vaccine. For children who have experienced a previous febrile seizure (from any cause) and those with a family history of febrile seizures there is a small increase in risk of febrile seizure following receipt of M-M-R II vaccine [see *Adverse Reactions (6)*].

#### **5.2 Hypersensitivity to Eggs**

Individuals with a history of anaphylactic, anaphylactoid, or other immediate reactions (e.g., hives, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) subsequent to egg ingestion may be at an enhanced risk of immediate-type hypersensitivity reactions after receiving M-M-R II vaccine. The potential risks and known benefits should be evaluated before considering vaccination in these individuals.

#### **5.3 Thrombocytopenia**

Transient thrombocytopenia has been reported within 4-6 weeks following vaccination with measles, mumps and rubella vaccine. Carefully evaluate the potential risk and benefit of vaccination in children with thrombocytopenia or in those who experienced thrombocytopenia after vaccination with a previous dose of measles, mumps, and rubella vaccine {6-8} [see *Adverse Reactions (6)*].

#### **5.4 Family History of Immunodeficiency**

Vaccination should be deferred in individuals with a family history of congenital or hereditary immunodeficiency until the individual's immune status has been evaluated and the individual has been found to be immunocompetent.

#### **5.5 Immune Globulins and Transfusions**

Immune Globulins (IG) and other blood products should not be given concurrently with M-M-R II [see *Drug Interactions (7.2)*]. These products may contain antibodies that interfere with vaccine virus replication and decrease the expected immune response.

The Advisory Committee on Immunization Practices (ACIP) has specific recommendations for intervals between administration of antibody containing products and live virus vaccines.

### **6 ADVERSE REACTIONS**

The following adverse reactions include those identified during clinical trials or reported during post-approval use of M-M-R II vaccine or its individual components.

#### *Body as a Whole*

Panniculitis; atypical measles; fever; headache; dizziness; malaise; irritability.

#### *Cardiovascular System*

Vasculitis.

#### *Digestive System*

Pancreatitis; diarrhea; vomiting; parotitis; nausea.

#### *Hematologic and Lymphatic Systems*

Thrombocytopenia; purpura; regional lymphadenopathy; leukocytosis.

#### *Immune System*

Anaphylaxis, anaphylactoid reactions, angioedema (including peripheral or facial edema) and bronchial spasm.

#### *Musculoskeletal System*

Arthritis; arthralgia; myalgia.

### *Nervous System*

Encephalitis; encephalopathy; measles inclusion body encephalitis (MIBE) subacute sclerosing panencephalitis (SSPE); Guillain-Barré Syndrome (GBS); acute disseminated encephalomyelitis (ADEM); transverse myelitis; febrile convulsions; afebrile convulsions or seizures; ataxia; polyneuritis; polyneuropathy; ocular palsies; paresthesia; syncope.

### *Respiratory System*

Pneumonia; pneumonitis; sore throat; cough; rhinitis.

### *Skin*

Stevens-Johnson syndrome; acute hemorrhagic edema of infancy; Henoch-Schönlein purpura; erythema multiforme; urticaria; rash; measles-like rash; pruritus; injection site reactions (pain, erythema, swelling and vesiculation).

### *Special Senses — Ear*

Nerve deafness; otitis media.

### *Special Senses — Eye*

Retinitis; optic neuritis; papillitis; conjunctivitis.

### *Urogenital System*

Epididymitis; orchitis.

In a randomized open-label clinical trial (NCT00432523), conducted in France and Germany, 752 children 12 months through 18 months of age received M-M-R II concomitantly administered with VARIVAX at a separate site, by either the intramuscular (n=374) or subcutaneous (n=378) route. In the overall population, 55.3% were male and the median age was 13.2 months. Local and systemic solicited adverse reactions were recorded by parents or guardians using standardized diary cards. Local solicited reactions were recorded for 4 days after vaccination, and systemic solicited adverse reactions were recorded for 42 days after vaccination. In the event that a participant experienced a rash or a mumps-like illness, parents and/or guardians were instructed to contact the investigator for an examination as soon as possible and no later than 72 hours following onset of symptoms. The nature of any rash was characterized by principal investigator either as a measles-like, rubella-like, varicella-like or "other." Study investigators reviewed the diary card with the participant or participant's legal guardian 42 days vaccination to ensure consistency with protocol definitions. Table 1 below presents the frequency of solicited adverse reactions based on the final assessment by the study investigators.

Table 1: Proportion of Participants Reporting Solicited Adverse Reactions Following Vaccination with M-M-R II, Concomitantly Administered with VARIVAX, by the Intramuscular or Subcutaneous Route

	INTRAMUSCULAR N=374 %	SUBCUTANEOUS N=376 %
Solicited injection-site reactions at MMR injection-site (Days 0 to 4)*		
Erythema†	10.4	16.2
Mild	8.8	13.0
Moderate	0.8	3.2
Severe	0	0
Missing	0.8	0
Pain†	7.0	7.2
Mild	5.1	5.9
Moderate	1.9	1.3
Severe	0	0

Swelling <sup>†</sup>	1.9	5.3
Mild	1.1	2.9
Moderate	0.5	1.1
Severe	0	0
Missing	0.3	1.3
Solicited systemic reactions (Days 0 to 42)		
Measles-like rash <sup>§</sup>	2.9	2.7
Rubella-like rash <sup>§</sup>	2.7	2.7
Varicella-like rash <sup>§</sup>	0.5	3.2
Mumps-like illness	0	0.3
Fever (temperature $\geq 38.0^{\circ}\text{C}$ ) <sup>¶, #</sup>	66.5	66.8
38.0-38.5°C	20.4	22.2
>38.5-39.0°C	17.4	16.6
>39.0-39.5°C	14.2	13.4
>39.5-40.0°C	11.8	11.0
>40.0°C	2.7	3.7

N=total number of participants in the group

\* During the post vaccination monitoring period (0-42 days), 3 participants experienced a varicella-like injection-site rash at the M-M-R II injection site. All were reported in the subcutaneous group.

<sup>†</sup> Intensity of injection site reaction: mild or  $\leq 2.5$  cm; moderate or  $> 2.5$  to  $\leq 5.0$  cm; severe or  $> 5.0$  cm

<sup>‡</sup> Intensity of pain: mild: awareness of symptom but easily tolerated; moderate: definitely acting like something is wrong; severe: extremely distressed or unable to do usual activities.

<sup>§</sup> Testing to distinguish between rash caused by wild-type or vaccine virus was not performed. Reports of measles-, rubella- and varicella-like rash included 3 reports of measles, 1 report of rubella, and 1 report of varicella, all with onset within 15 days post-vaccination.

<sup>¶</sup> The percentage of fever is defined within the population who had valid temperature measurements. One participant in IM group and two participants in SC group did not have temperature measurements and were excluded from the denominator; resulting in N=373 and N=374, respectively.

<sup>#</sup> In the IM Group 92.3% of fevers were documented using the rectal route of measurement and 7.7% of fevers were documented only by the axillary route of measurement. In the SC Group 89.6% of fevers were documented using the rectal route of measurement and 10.4% of fevers were documented only by the axillary route of measurement.

Unsolicted adverse events that occurred within 42 days following vaccination were recorded using diary cards supplemented by medical review. Data on unsolicted adverse events were transcribed into the study database during an on-site visit at day 42. The rates and types of reported adverse events (AEs) across groups were similar and included common clinical events that are often reported in the evaluated populations. Serious adverse events occurred at rates of 0.3% and 1% in the intramuscular and subcutaneous groups, respectively. One moderate intensity case of otitis media occurred in a participant in the subcutaneous group was considered related to the study vaccination.

## 7 DRUG INTERACTIONS

### 7.1 Corticosteroids and Immunosuppressive Drugs

M-M-R II vaccine should not be administered to individuals receiving immunosuppressive therapy, including high dose corticosteroids. Vaccination with M-M-R II vaccine can result in disseminated disease due to measles vaccine in individuals on immunosuppressive drugs [see *Contraindications (4.2)*].

## 7.2 Immune Globulins and Transfusions

Administration of immune globulins and other blood products concurrently with M-M-R II vaccine may interfere with the expected immune response {9-11} [see *Warnings and Precautions (5.5)*]. The ACIP has specific recommendations for intervals between administration of antibody containing products and live virus vaccines.

## 7.3 Tuberculin Skin Testing

It has been reported that live attenuated measles, mumps and rubella virus vaccines given individually may result in a temporary depression of tuberculin skin sensitivity. Therefore, if a tuberculin skin test with tuberculin purified protein derivative (PPD) is to be done, it should be administered before, simultaneously with, or at least 4 to 6 weeks after vaccination with M-M-R II vaccine.

## 7.4 Use with Other Live Viral Vaccines

M-M-R II vaccine can be administered concurrently with other live viral vaccines. If not given concurrently, M-M-R II vaccine should be given one month before or one month after administration of other live viral vaccines to avoid potential for immune interference.

# 8 USE IN SPECIFIC POPULATIONS

## 8.1 Pregnancy

### Risk Summary

M-M-R II vaccine is contraindicated for use in pregnant women because infection during pregnancy with the wild-type viruses has been associated with maternal and fetal adverse outcomes.

Increased rates of spontaneous abortion, stillbirth, premature delivery and congenital defects have been observed following infection with wild-type measles during pregnancy. {12,13} Wild-type mumps infection during the first trimester of pregnancy may increase the rate of spontaneous abortion.

Infection with wild-type rubella during pregnancy can lead to miscarriage or stillbirth. If rubella infection occurs during the first trimester of pregnancy, it can result in severe congenital defects, Congenital Rubella Syndrome (CRS). Congenital Rubella Syndrome in the infant includes but is not limited to eye manifestations (cataracts, glaucoma, retinitis), congenital heart defects, hearing loss, microcephaly, and intellectual disabilities. M-M-R II vaccine contains live attenuated measles, mumps and rubella viruses. It is not known whether M-M-R II vaccine can cause fetal harm when administered to pregnant woman. There are no adequate and well-controlled studies of M-M-R II vaccine administration to pregnant women.

All pregnancies have a risk of birth defect, loss or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Available data suggest the rates of major birth defects and miscarriage in women who received M-M-R II vaccine within 30 days prior to pregnancy or during pregnancy are consistent with estimated background rates (see *Data*).

### Data

#### Human Data

A cumulative assessment of post-marketing reports for M-M-R II vaccine from licensure 01 April 1978 through 31 December 2018, identified 796 reports of inadvertent administration of M-M-R II vaccine occurring 30 days before or at any time during pregnancy with known pregnancy outcomes. Of the prospectively followed pregnancies for whom the timing of M-M-R II vaccination was known, 425 women received M-M-R II vaccine during the 30 days prior to conception through the second trimester. The outcomes for these 425 prospectively followed pregnancies included 16 infants with major birth defects, 4 cases of fetal death and 50 cases of miscarriage. No abnormalities compatible with congenital rubella syndrome have been identified in patients who received M-M-R II vaccine. Rubella vaccine virus can cross the placenta, leading to asymptomatic infection of the fetus. Mumps vaccine virus has also been shown to infect the placenta {14}, but there is no evidence that it causes congenital malformations or disease in the fetus or infant.

The CDC established the Vaccine in Pregnancy registry (1971-1989) of women who had received rubella vaccines within 3 months before or after conception. Data on 1221 inadvertently vaccinated pregnant women demonstrated no evidence of an increase in fetal abnormalities or cases of Congenital Rubella Syndrome (CRS) in the enrolled women {15}.

## **8.2 Lactation**

### **Risk Summary**

It is not known whether measles or mumps vaccine virus is secreted in human milk. Studies have shown that lactating postpartum women vaccinated with live attenuated rubella vaccine may secrete the virus in breast milk and transmit it to breast-fed infants. {16,17} In the breast-fed infants with serological evidence of rubella virus vaccine strain antibodies, none exhibited severe disease; however, one exhibited mild clinical illness typical of acquired rubella. {18,19}

The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for M-M-R II, and any potential adverse effects on the breastfed child from M-M-R II or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

### **8.4 Pediatric Use**

M-M-R II vaccine is not approved for individuals less than 12 months of age. Safety and effectiveness of measles vaccine in infants below the age of 6 months have not been established [see *Clinical Studies (14)*]. Safety and effectiveness of mumps and rubella vaccine in infants less than 12 months of age have not been established.

### **8.5 Geriatric Use**

Clinical studies of M-M-R II did not include sufficient numbers of seronegative subjects aged 65 and over to determine whether they respond differently from younger subjects.

## **11 DESCRIPTION**

M-M-R II vaccine is a sterile lyophilized preparation of (1) Measles Virus Vaccine Live, an attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; (2) Mumps Virus Vaccine Live, the Jeryl Lynn™ (B level) strain of mumps virus propagated in chick embryo cell culture; and (3) Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts. {20,21} The cells, virus pools, recombinant human serum albumin and fetal bovine serum used in manufacturing are tested and determined to be free of adventitious agents.

After reconstitution, each approximately 0.5 mL dose contains not less than 3.0 log<sub>10</sub> TCID<sub>50</sub> (tissue culture infectious doses) of measles virus; 4.1 log<sub>10</sub> TCID<sub>50</sub> of mumps virus; and 3.0 log<sub>10</sub> TCID<sub>50</sub> of rubella virus.

Each dose is calculated to contain sorbitol (14.5 mg), sucrose (1.9 mg), hydrolyzed gelatin (14.5 mg), recombinant human albumin (≤0.3 mg), fetal bovine serum (<1 ppm), approximately 25 mcg of neomycin and other buffer and media ingredients. The product contains no preservative.

## **12 CLINICAL PHARMACOLOGY**

### **12.1 Mechanism of Action**

M-M-R II vaccination induces antibodies to measles, mumps, and rubella associated with protection which can be measured by neutralization assays, hemagglutination-inhibition (HI) assays, or enzyme linked immunosorbent assay (ELISA) tests. Results from efficacy studies or effectiveness studies that were previously conducted for the component vaccines of M-M-R II were used to define levels of serum antibodies that correlated with protection against measles, mumps, and rubella [see *Clinical Studies (14)*].

### **12.4 Persistence of Antibody Responses After Vaccination**

Neutralizing and ELISA antibodies to measles, mumps, and rubella viruses are still detectable in 95-100%, 74-91%, and 90-100% of individuals respectively, 11 to 13 years after primary vaccination. {22-28}

## **13 NONCLINICAL TOXICOLOGY**

### **13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility**

M-M-R II vaccine has not been evaluated for carcinogenic or mutagenic potential or impairment of fertility.



## 14 CLINICAL STUDIES

### 14.1 Clinical Efficacy

Efficacy of measles, mumps, and rubella vaccines was established in a series of double-blind controlled trials. {29-34} These studies also established that seroconversion in response to vaccination against measles, mumps and rubella paralleled protection. {35-38}

### 14.2 Immunogenicity

Clinical studies enrolling 284 triple seronegative children, 11 months to 7 years of age, demonstrated that subcutaneously administered M-M-R II vaccine is immunogenic. In these studies, a single subcutaneous injection of the vaccine induced measles HI antibodies in 95%, mumps neutralizing antibodies in 96%, and rubella HI antibodies in 99% of susceptible individuals.

A study of 6-month-old and 15-month-old infants born to mothers vaccinated with a measles vaccine in childhood, demonstrated that, following infant and toddler vaccination subcutaneously with Measles Virus Vaccine, Live (previously US-licensed, manufactured by Merck), 74% of the 6-month-old infants developed detectable neutralizing antibody titers while 100% of the 15-month-old infants vaccinated with Measles Virus Vaccine, Live or M-M-R II vaccine developed neutralizing antibodies {39}. When the 6-month-old infants of immunized mothers were revaccinated at 15 months with M-M-R II vaccine, they developed antibody titers similar to those of toddlers who were vaccinated previously at 15-months of age.

In an open label clinical trial (NCT00432523) 752 children 12 through 18 months of age received M-M-R II either intramuscularly (n=374) or subcutaneously (n=378), concomitantly with VARIVAX. Antibody responses to measles, mumps, and rubella viruses were measured by ELISAs using sera obtained 6 weeks postvaccination. For anti-measles virus, anti-mumps virus and anti-rubella virus, seroresponse rates were defined as the percentage of children seronegative at baseline who achieved antibody titers above the respective seroresponse threshold for each assay 6 weeks post vaccination. Seroresponse thresholds were defined as 255 mIU/mL, 10 EU/mL, and 10 IU/mL for anti-measles virus, anti-mumps virus, and anti-rubella virus antibodies, respectively. For each vaccine antigen at least 89% of enrolled children were seronegative at baseline. In a post hoc analysis, seroresponse rates to mumps and rubella viruses were noninferior for the intramuscular group compared to the subcutaneous group (the lower bound of the 95% confidence interval for the difference in seroresponse rates [intramuscular group minus subcutaneous group]  $\geq$ -5%). While the seroresponse rate to measles virus narrowly missed meeting the post hoc criterion of -5% for noninferiority (lower bound of the 95% CI for the difference in seroresponse rate -5.28%), it met the pre-specified criterion using a -10% noninferiority margin. For measles, mumps and rubella antigens the lower bound of the 95% CI of the seroresponse rates was >90% after intramuscular administration. The point estimates of the proportions of children achieving antibody titers above the seroresponse thresholds for measles, mumps, and rubella viruses were as follows: 94.3%, 97.7%, and 98.1%, respectively, in the intramuscular group and 96.1%, 98.1%, and 98.1%, respectively, in the subcutaneous group.

## 15 REFERENCES

1. General Recommendations on Immunization, Recommendations of the Advisory Committee on Immunization Practices, MMWR 43(RR-1): 1-38, January 28, 1994.
2. Measles, Mumps, and Rubella — Vaccine Use and Strategies for Elimination of Measles, Rubella, and Congenital Rubella Syndrome and Control of Mumps: Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR 47(RR-8): May 22, 1998.
3. Kelso, J.M.; Jones, R.T.; Yunginger, J.W.: Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin, J. Allergy Clin. Immunol. 91: 867-872, 1993.
4. Bitnum, A.; et al: Measles Inclusion Body Encephalitis Caused by the Vaccine Strain of Measles Virus. Clin. Infect. Dis. 29: 855-861, 1999.
5. Angel, J.B.; et al: Vaccine Associated Measles Pneumonitis in an Adult with AIDS. Annals of Internal Medicine, 129: 104-106, 1998.
6. Cecinati V, et al. Vaccine administration and the development of immune thrombocytopenic purpura in children. Human Vaccines & Immunotherapeutics 9:5, 2013.
7. Mantadakis E, Farmaki E, Buchanan GR. Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management. J Ped 156(4): 2010.

8. Andrews N, Stowe J, Miller E, Svanstrom H, Johansen K, Bonhoeffer J, et al. A collaborative approach to investigating the risk of thrombocytopenic purpura after measles-mumps-rubella vaccination in England and Denmark. *Vaccine*. 2012;30:3042-6.
9. Rubella Prevention: Recommendation of the Immunization Practices Advisory Committee (ACIP), *MMWR* 39(RR-15): 1-18, November 23, 1990.
10. Peter, G.; et al (eds): Report of the Committee on Infectious Diseases, Twenty-fourth Edition, American Academy of Pediatrics, 344-357, 1997.
11. Measles Prevention: Recommendations of the Immunization Practices Advisory Committee (ACIP), *MMWR* 38(S-9): 5-22, December 29, 1989.
12. Eberhart-Phillips, J.E.; et al: Measles in pregnancy: a descriptive study of 58 cases. *Obstetrics and Gynecology*, 82(5): 797-801, November 1993.
13. Jespersen, C.S.; et al: Measles as a cause of fetal defects: A retrospective study of ten measles epidemics in Greenland. *Acta Paediatr Scand*. 66: 367-372, May 1977.
14. Yamauchi T, Wilson C, Geme JW Jr. Transmission of live, attenuated mumps virus to the human placenta. *N Engl J Med*. 1974;290(13):710-712.
15. Rubella Vaccination during Pregnancy —United States, 1971-1988. *JAMA*. 1989;261(23):3374–3383.
16. Losonsky, G.A.; Fishaut, J.M.; Strussenber, J.; Ogra, P.L.: Effect of immunization against rubella on lactation products. II. Maternal-neonatal interactions, *J. Infect. Dis*. 145: 661-666, 1982.
17. Losonsky, G.A.; Fishaut, J.M.; Strussenber, J.; Ogra, P.L.: Effect of immunization against rubella on lactation products. I. Development and characterization of specific immunologic reactivity in breast milk, *J. Infect. Dis*. 145: 654-660, 1982.
18. Landes, R.D.; Bass, J.W.; Millunchick, E.W.; Oetgen, W.J.: Neonatal rubella following postpartum maternal immunization, *J. Pediatr*. 97: 465-467, 1980.
19. Lerman, S.J.: Neonatal rubella following postpartum maternal immunization, *J. Pediatr*. 98: 668, 1981. (Letter)
20. Plotkin, S.A.; Cornfeld, D.; Ingalls, T.H.: Studies of immunization with living rubella virus: Trials in children with a strain cultured from an aborted fetus, *Am. J. Dis. Child*. 110: 381-389, 1965.
21. Plotkin, S.A.; Farquhar, J.; Katz, M.; Ingalls, T.H.: A new attenuated rubella virus grown in human fibroblasts: Evidence for reduced nasopharyngeal excretion, *Am. J. Epidemiol*. 86: 468-477, 1967.
22. Weibel, R.E.; Carlson, A.J.; Villarejos, V.M.; Buynak, E.B.; McLean, A.A.; Hilleman, M.R.: Clinical and Laboratory Studies of Combined Live Measles, Mumps, and Rubella Vaccines Using the RA 27/3 Rubella Virus, *Proc. Soc. Exp. Biol. Med*. 165: 323-326, 1980.
23. Watson, J.C.; Pearson, J.S.; Erdman, D.D.; et al: An Evaluation of Measles Revaccination Among School-Entry Age Children, 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Abstract #268, 143, 1991.
24. Unpublished data from the files of Merck Research Laboratories.
25. Davidkin, I.; Jokinen, S.; Broman, M. et al.: Persistence of Measles, Mumps, and Rubella Antibodies in an MMR-Vaccinated Cohort: A 20-Year Follow-up, *JID* 197:950–6, April 2008.
26. LeBaron, W.; Beeler J.; Sullivan, B.; et al.: Persistence of Measles Antibodies After 2 Doses of Measles Vaccine in a Postelimination Environment, *Arch Pediatr Adolesc Med*. 161:294-301, March 2007.
27. LeBaron, C.; Forghani, B.; Beck, C. et al.: Persistence of Mumps Antibodies after 2 Doses of Measles-Mumps-Rubella Vaccine, *JID* 199:552– 60 , February 2009.
28. LeBaron, W.; Forghani, B.; Matter, L. et al.: Persistence of Rubella Antibodies after 2 Doses of Measles-Mumps-Rubella Vaccine, *JID* 200:888–99, September 2009.
29. Hilleman, M.R.; Buynak, E.B.; Weibel, R.E.; et al: Development and Evaluation of the Moraten Measles Virus Vaccine, *JAMA* 206(3): 587-590, 1968.
30. Weibel, R.E.; Stokes, J.; Buynak, E.B.; et al: Live, Attenuated Mumps Virus Vaccine 3. Clinical and Serologic Aspects in a Field Evaluation, *N. Engl. J. Med*. 276: 245-251, 1967.
31. Hilleman, M.R.; Weibel, R.E.; Buynak, E.B.; et al: Live, Attenuated Mumps Virus Vaccine 4. Protective Efficacy as Measured in a Field Evaluation, *N. Engl. J. Med*. 276: 252-258, 1967.
32. Cutts, F.T.; Henderson, R.H.; Clements, C.J.; et al: Principles of measles control, *Bull WHO* 69(1): 1-7, 1991.
33. Weibel, R.E.; Buynak, E.B.; Stokes, J.; et al: Evaluation Of Live Attenuated Mumps Virus Vaccine, Strain Jeryl Lynn, First International Conference on Vaccines Against Viral and Rickettsial Diseases of Man, World Health Organization, No. 147, May 1967.
34. Leibhaber, H.; Ingalls, T.H.; LeBouvier, G.L.; et al: Vaccination With RA 27/3 Rubella Vaccine, *Am. J. Dis. Child*. 123: 133-136, February 1972.

35. Rosen, L.: Hemagglutination and Hemagglutination-Inhibition with Measles Virus, *Virology* 13: 139-141, January 1961.
36. Brown, G.C.; et al: Fluorescent-Antibody Marker for Vaccine-Induced Rubella Antibodies, *Infection and Immunity* 2(4): 360-363, 1970.
37. Buynak, E.B.; et al: Live Attenuated Mumps Virus Vaccine 1. Vaccine Development, *Proceedings of the Society for Experimental Biology and Medicine*, 123: 768-775, 1966.
38. Hilleman M.R., Studies of Live Attenuated Measles Virus Vaccine in Man: II. Appraisal of Efficacy. *Amer. J. of Public Health*, 52(2):44-56, 1962.
39. Johnson, C.E.; et al: Measles Vaccine Immunogenicity in 6- Versus 15-Month-Old Infants Born to Mothers in the Measles Vaccine Era, *Pediatrics*, 93(6): 939-943, 1994.

## 16 HOW SUPPLIED/STORAGE AND HANDLING

No. 4681 — M-M-R II vaccine is supplied as follows:

(1) a box of 10 single-dose vials of lyophilized vaccine (package A), NDC 0006-4681-00

(2) a box of 10 vials of diluent (package B)

Exposure to light may inactivate the vaccine viruses.

**To maintain potency, M-M-R II must be stored between -58°F and +46°F (-50°C to +8°C). Use of dry ice may subject M-M-R II to temperatures colder than -58°F (-50°C).**

Before reconstitution, refrigerate the lyophilized vaccine at 36°F to 46°F (2°C to 8°C).

Store accompanying diluent in the refrigerator (36°F to 46°F, 2°C to 8°C) or at room temperature (68°F to 77°F, 20°C to 25°C). **Do not freeze the diluent.**

Administer M-M-R II vaccine as soon as possible after reconstitution. If not administered immediately, reconstituted vaccine may be stored between 36°F to 46°F (2°C to 8°C), protected from light, for up to 8 hours. Discard reconstituted vaccine if it is not used within 8 hours.

**For information regarding the product or questions regarding storage conditions, call 1-800-MERCK-90 (1-800-637-2590).**

## 17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Package Insert).

Discuss the following with the patient:

- Provide the required vaccine information to the patient, parent, or guardian.
- Inform the patient, parent, or guardian of the benefits and risks associated with vaccination.
- Question the patient, parent, or guardian about reactions to a previous dose of M-M-R II vaccine or other measles-, mumps-, or rubella-containing vaccines.
- Question females of reproductive potential regarding the possibility of pregnancy. Inform female patients to avoid pregnancy for 1 month following vaccination [*see Contraindications (4.5) and Use in Specific Populations (8.1)*].
- Inform the patient, parent, or guardian that vaccination with M-M-R II may not offer 100% protection from measles, mumps, and rubella infection.
- Instruct patients, parents, or guardians to report any adverse reactions to their health-care provider. The U.S. Department of Health and Human Services has established a Vaccine Adverse Event Reporting System (VAERS) to accept all reports of suspected adverse events after the administration of any vaccine, including but not limited to the reporting of events required by the National Childhood Vaccine Injury Act of 1986. For information or a copy of the vaccine reporting form, call the VAERS toll-free number at 1-800-822-7967, or report online at <https://www.vaers.hhs.gov>.

Distributed by: Merck Sharp & Dohme Corp., a subsidiary of  
 **MERCK & CO., INC.**, Whitehouse Station, NJ 08889, USA

For patent information: [www.merck.com/product/patent/home.html](http://www.merck.com/product/patent/home.html)

Copyright © 1978-2023 Merck Sharp & Dohme Corp., a subsidiary of **Merck & Co., Inc.**

All rights reserved.

uspi-v205c-i-2303r012